Tenofovir disoproxil fumarate oral tablet and preparation method thereof

A technology of tenofovir fumarate and disoproxil, which can be applied in the directions of non-active ingredient medical preparations, medical preparations containing active ingredients, and pill delivery, etc., can solve the problem of reduced bioavailability, swallowing problems, Dissolution reduction and other problems, to achieve the effect of reducing tablet volume, reducing product cost, and reducing the amount of excipients

Inactive Publication Date: 2016-01-06
REGENEX PHARMA LTD
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This property leads to the situation of "collapsing but not dispersing" in the preparation, which reduces the dissolution rate and bioavailability. In view of this situation, the usual solution is to increase the amount of excipients to reduce the contact between raw materials. The current application Tenofovir disoproxil fumarate tablets (Gilead Sciences) took this approach, although the dissolution of its formulations reached a reasonable level, fast dissolution, fasting oral bioavailability reached 25% , but the weight of the tablet increases, and the proportion of active ingredients in the weight of the tablet is only about 45%
In order to prevent unreasonable drug specifications from causing confusion to clinical medication, the State Food and Drug Administration requires that the dosage should be reasonably determined according to the usage and dosage of the drug, generally not less than the minimum single dosage, tenofovir disoproxil fumarate single dosage The dosage is 300mg, and the total weight of oral tablets containing tenofovir disoproxil fumarate 300mg reaches 700mg. If the tablet is too large and heavy, it will cause certain swallowing problems, especially for some such as the elderly and children. Poor compliance with patients with dysphagia
[0004] CN201110141124 solves the problem of dysphagia by preparing tenofovir disoproxil fumarate into dispersible tablet pharmaceutical preparations, but in the product

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tenofovir disoproxil fumarate oral tablet and preparation method thereof
  • Tenofovir disoproxil fumarate oral tablet and preparation method thereof
  • Tenofovir disoproxil fumarate oral tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] prescription:

[0032] Material composition Prescription ratio (g) Tenofovir disoproxil fumarate300.0 Microcrystalline cellulose136.4 Mannitol50.5 Sodium starch glycolate27.3 Crospovidone5.5 Micronized silica gel5.6 Pregelatinized starch20.2 Production volume 1000 pieces

[0033] Preparation method: 1) Weigh each material separately; 2) Take 400ml of purified water (10℃), add pregelatinized starch under stirring, stir well for 10 minutes, and prepare about 5% (w / v) pregel Starch suspension; 3) Mix tenofovir disoproxil fumarate, microcrystalline cellulose, mannitol, and sodium starch glycolate fully, mix and add pregelatinized starch suspension to make soft material , Extrusion granulation; 4) Dry the granules in the drying box until the moisture of the granules is not more than 1.5%, and the drying temperature is 55℃; 5) The dried granules are passed through a 20-mesh sieve to be granulated; 6) After granulation, the granules are added to crospovidone Mix with ...

Embodiment 2

[0035] prescription:

[0036] Material composition Prescription ratio (g) Tenofovir disoproxil fumarate300.0 lactose46.0 Low-substituted hydroxypropyl cellulose12.0 Low-substituted hydroxypropyl cellulose6.0 talcum powder15.0 Pregelatinized starch21.0 Production volume 1000 pieces

[0037] Preparation method: 1) Weigh each material separately; 2) Take 100ml of purified water (20℃), add pregelatinized starch, fully stir for 45 minutes, and prepare about 20% (w / v) pregelatinized starch suspension 3) Put tenofovir disoproxil fumarate, lactose, and 12.0 g of low-substituted hydroxypropyl cellulose in a high-speed stirring granulator to mix, and then add the pregelatinized starch suspension for granulation; 4) The wet granules are dried in a fluidized bed granulator until the moisture of the granules is not more than 1.5%, and the drying temperature is 60℃; 5) The dried granules are sieved through an 18-mesh sieve; 6.0g and total talc powder; 7) Press the theoretical tablet...

Embodiment 3

[0039] prescription:

[0040] Material composition Prescription ratio (g) Tenofovir disoproxil fumarate300.0 lactose42.8 Powdered sugar25.8 Low-substituted hydroxypropyl cellulose10.8 Sodium starch glycolate5.2 Micronized silica gel1.2 Pregelatinized starch42.8 Production volume 1000 pieces

[0041] Preparation method: 1) Weigh each material separately; 2) Take 85ml of ethanol aqueous solution [Ethanol 30% (v / v), 25℃], add pregelatinized starch under stirring, fully stir for 20 minutes, and configure it to about 25 %(W / v) pregelatinized starch suspension; 3) Pass tenofovir disoproxil fumarate, lactose, powdered sugar, low-substituted hydroxypropyl cellulose, pregelatinized starch suspension through Fluidized bed granulation machine is granulated; and dried until the moisture of the granules is not more than 1.5%, and the drying temperature is 50℃; 4) The dried granules are passed through an 18-mesh sieve to be granulated; 5) After granulation, the granules are mixed wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a tenofovir disoproxil fumarate oral tablet and a preparation method thereof. Normal-temperature solution (10-30DEG C) is adopted for preparing pregelatinized starch to serve as an adhesive. The pregelatinized starch in a suspension state is capable of wrapping raw materials to some extent to prevent gathering of the raw materials, gelatinization of pregelatinized starch suspension prepared at the normal temperature is avoided, a disintegration function of the starch is reserved, and since an adhesive action is limited, influences on dissolution due to overlarge particle hardness is avoided. Consumption of auxiliary materials is reduced on the basis of keeping similar dissolubility to existing tablets, total tablet weight can be reduced by 20-40% approximately, tablet size is greatly reduced, and accordingly difficulty in swallowing is lowered, and patients can take the tablet more easily.

Description

Technical field [0001] The invention relates to an oral tablet of tenofovir disoproxil fumarate and a preparation method thereof. Background technique [0002] Tenofovir disoproxil fumarate (Tenofovirdisoproxilfumarate) is an ester prodrug of tenofovir, which belongs to a new type of nucleotide reverse transcriptase inhibitor. After oral administration, it is hydrolyzed to tenofovir and then Phosphorylation of cellular kinases produces pharmacologically active metabolite tenofovir diphosphate. The latter competes with 5'-deoxyadenosyl triphosphate and participates in the synthesis of viral DNA. After entering the viral DNA, it lacks 3'-OH groups. Clusters, which leads to blocking of DNA elongation, thereby blocking virus replication. Because of its significant anti-hepatitis B virus and anti-HIV curative effects, no / low drug resistance, and low toxicity to the human body, it has obvious clinical advantages. The dosage used to treat HIV and HBV infection is oral, daily Once, 300...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K31/675A61K47/36A61K9/30A61P31/18A61P31/20
Inventor 覃桂顺黄和意陶艳周雨华彭贵子汤丹袁永玲左联卢智俊
Owner REGENEX PHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products